Evofem Biosciences Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Product sales, net | $3,603 | $5,809 |
| Operating Expenses: | ||
| Cost of goods sold | 684 | 1,376 |
| Research and development | 594 | 540 |
| Selling and marketing | 2,345 | 3,854 |
| General and administrative | 2,824 | 3,618 |
| Total operating expenses | 6,447 | 9,388 |
| Loss from operations | (2,844) | (3,579) |
| Other income (expense): | ||
| Interest income | 4 | 18 |
| Other expense, net | (616) | (318) |
| Loss on issuance of financial instruments (Note 8) | (3,275) | (84) |
| Gain on debt extinguishment | 1,120 | - |
| Change in fair value of financial instruments (Note 6) | 802 | 1,612 |
| Total other income (expense), net | (1,965) | 1,228 |
| Loss before income tax | (4,809) | (2,351) |
| Income tax expense | - | (3) |
| Net loss | (4,809) | (2,354) |
| Convertible preferred stock deemed dividends | (47) | - |
| Net loss attributable to common stockholders | $(4,856) | $(2,354) |
| Net loss per share attributable to common stockholders | ||
| (basic and diluted): | $(0.16) | $(1.85) |
| Weighted-average shares used to compute net | ||
| loss per share attributable to common shareholders (basic and diluted): | 31,194,393 | 1,271,524 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.